Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy

The aim of our study is firstly to evaluate the prevalence and prognostic value of nutrition risk in gastric cancer patients and secondly to explore whether the nutrition support can prolong the survival of advanced gastric cancer patients. It contained two study periods. In the first period, we prospectively evaluated the nutritional risk of gastric adenocarcinoma patients from 2009 to 2011 using the method of European Nutritional Risk Screening (NRS) 2002. The Kaplan-Meier method and log-rank test were used to evaluate the prognostic value of high nutrition risk. The second period was between 2012 and 2013. We prospectively gave the nutrition support to stage IV gastric cancer patients whose NRS is a parts per thousand yen3. There were 830 patients in the first period, 50.7 % patients with a NRS a parts per thousand yenaEuro parts per thousand 3. Patients with NRS a parts per thousand yenaEuro parts per thousand 3 presented a significantly higher percentage of stage IV diseases, elevated values of C-reactive protein, and hypoproteinemia. The median survival was significantly higher in NRS < 3 patients (31.9 vs. 25.7 months, P < 0.001). Multivariate analysis confirmed that NRS status was an independent prognostic factor. There were 347 patients in the second period. Young, male, and good response to chemotherapy were more likely to have the NRS shift to < 3 after nutrition support. The median survival was 14.3 and 9.6 months for patients with and without NRS shift, respectively, P = 0.001. NRS a parts per thousand yenaEuro parts per thousand 3 was an independent adverse prognostic factor in gastric cancer patients. For stage IV patients whose NRS a parts per thousand yenaEuro parts per thousand 3, the nutrition support might be helpful to improve the prognosis.